jun 4, 2019: 3:15 p.m. - 4:15 p.m.
106AB, Level 100
The Opioid Crisis has had grave effects on both the public health and the well-being of our society. Despite tremendous advances in neuroscience in recent years, novel treatments for pain and addiction, including opioid use disorder, have been woefully lacking. A new paradigm is needed to spur the development of treatments for those suffering from the devastation of addiction. During this interactive session, senior leaders from across the spectrum of the bio-pharmaceutical sector and government will discuss creative ways to foster medication development for addiction. Specifically, novel ways to leverage the resources of the National Institutes of Health will be proposed, so that a new archetype in which the NIH can serve as a catalyst for medication development in the private sector can emerge. Thoughts and feedback from the audience will be crucial to help refine this novel paradigm to help achieve the maximum impact on the public health.